Integrating Angiogenic, Inflamatory and Molecular Biomarkers for Early Prediction of Preeclampsia : A Comprehensive Systematic Review
The International Journal of Medical Science and Health Research · 02.08.2026 · 48 (4) · 439-496
DOI: 10.70070/2g3n0268 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 02.08.2026. Verfasst von Muhammad Abni Setiawan und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity and mortality worldwide. Early prediction remains challenging due to its multifactorial pathophysiology. This systematic review evaluates the predictive performance of angiogenic, inflammatory, and molecular biomarkers for early PE prediction.
Methods
We screened 80 studies (that examined biomarkers in pregnant women, reported predictive accuracy, and included comparison groups. Data extraction focused on single and multi-marker performance, prediction timing, and clinical applicability.
Results
Angiogenic markers were most studied. Low PlGF and elevated sFlt-1 consistently predicted PE, with the sFlt-1/PlGF ratio showing pooled sensitivity 80%, specificity 92% (AUC 0.90–0.95). For short-term rule-out, sFlt-1/PlGF ≤38 had 99.3% negative predictive value for PE within one week. First-trimester multi-omics models (e.g., leptin/ceramide ratio, cell-free RNA panels) achieved AUC 0.85–0.94, detecting risk up to 18 weeks before onset. Inflammatory markers (CA-125, IL-6, TNF-α) and molecular markers (microRNAs, MMP-7, PAPP-A) showed moderate individual performance but improved in combination. Early-onset PE was more accurately predicted than late-onset disease. Machine learning and multi-marker integration consistently outperformed single biomarkers.
Discussion
The sFlt-1/PlGF ratio is the most clinically validated biomarker for short-term rule-out in symptomatic women. First-trimester multi-marker screening enables aspirin prophylaxis in high-risk women. However, standardization, cost-effectiveness, and population-specific validation remain challenges.
Conclusion
Integrating angiogenic, inflammatory, and molecular biomarkers significantly improves early PE prediction compared to single markers. The sFlt-1/PlGF ratio is ready for clinical use for short-term prediction. Future research should validate multi-omics panels in diverse populations and integrate placental pathology.
Zitieren
APA
Setiawan, M. A., Rumopa, H. I. M., & Setiani, I. Y. (2026). Integrating Angiogenic, Inflamatory and Molecular Biomarkers for Early Prediction of Preeclampsia : A Comprehensive Systematic Review. The International Journal of Medical Science and Health Research, 48(4), 439-496. https://doi.org/10.70070/2g3n0268
Vancouver
Setiawan MA, Rumopa HIM, Setiani IY. Integrating Angiogenic, Inflamatory and Molecular Biomarkers for Early Prediction of Preeclampsia : A Comprehensive Systematic Review. The International Journal of Medical Science and Health Research. 2026;48(4):439-496. doi:10.70070/2g3n0268
BibTeX
@article{Setiawan2026,
author = {Setiawan, Muhammad Abni and Rumopa, Harold Imanuel Marcelliano and Setiani, Irene Yemima},
title = {Integrating Angiogenic, Inflamatory and Molecular Biomarkers for Early Prediction of Preeclampsia : A Comprehensive Systematic Review},
journal = {The International Journal of Medical Science and Health Research},
year = {2026},
volume = {48},
number = {4},
pages = {439--496},
doi = {10.70070/2g3n0268}
}
EUVIMED